Rhea-AI Summary
Panbela Therapeutics (Nasdaq: PBLA) is conducting a Phase 1 clinical trial of SBP-101, an investigational agent for patients with metastatic pancreatic ductal adenocarcinoma (PDA), in combination with standard care agents gemcitabine and nab-paclitaxel. The independent data safety monitoring board (DSMB) has recommended pausing SBP-101 dosing due to reports of visual disturbances in some patients, while other trial activities will continue. Panbela is finalizing a visual screening program and remains confident in SBP-101's potential benefits. All trial enrollments were completed by December 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.59%
Tags
FAQ
What is the current stock price of PANBELA THERAPEUTICS (PBLA)?
The current stock price of PANBELA THERAPEUTICS (PBLA) is $0.000001 as of October 2, 2026.
What is the market cap of PANBELA THERAPEUTICS (PBLA)?
The market cap of PANBELA THERAPEUTICS (PBLA) is approximately 242.7K.